SCHEMBL19848288

SCHEMBL19848288

Cc1cc2nnn(S(=O)(=O)c3ccccc3)c2cc1C

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 2/20 0.65
TSHR P16473 3/20 0.53
HSD17B10 Q99714 2/20 0.53
KMT2A Q03164 1/20 0.53
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 4/20 0.50
MGAM O43451 3/20 0.50
AMY1A P0DUB6 3/20 0.50
SI P14410 3/20 0.50
MGAM2 Q2M2H8 3/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
POLB P06746 1/20 0.49
NPSR1 Q6W5P4 3/20 0.44
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.43
KDM4E B2RXH2 1/20 0.42
BRD4 O60885 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19911461 0.85 SLC9A1 (0.47) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19911490 0.84 SLC9A1 (0.69) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19848576 0.84 SLC9A1 (0.69) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL29479875 0.79 SLC9A1 (1.00) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL2491809 0.79 SLC9A1 (1.00) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19848354 0.78 SLC9A1 (0.68) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19911621 0.78 SLC9A1 (0.68) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19911636 0.78 SLC9A1 (0.68) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL19848551 0.78 SLC9A1 (0.68) SLC9A1TSHRHSD17B10KMT2ACYP2C19
SCHEMBL2958185 0.78 SLC9A1 (0.97) SLC9A1TSHRHSD17B10KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-3279997-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2018-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 SLC9A1 341/4885TSHR 2034/4885HSD17B10 2395/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 SLC9A1 341/4885TSHR 2034/4885HSD17B10 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.